Placenta Previa and Placental Abruption

Placental Abruption—Placental Separation Mechanisms

• Mechanical separation and hemorrhage initiation: Separation of placental tissue from the decidua basalis disrupts the spiral arteries at the implantation site, triggering acute hemorrhage into the decidua. This maternal bleed dissects between the placenta and uterine wall (retroplacental hemorrhage), creating an expanding hematoma that further peels the placenta away from the myometrium. The volume of vaginal bleeding does not correlate with severity of abruption, as substantial hemorrhage may be concealed (retained within the uterus beneath the placenta) or revealed (expressing vaginally). This distinction is critical for clinical assessment.

• Placental insufficiency and fetal hypoxemia: As the placental surface area becomes separated from maternal circulation, the functional capacity for maternal-fetal gas exchange, nutrient transfer, and waste removal becomes progressively compromised. Fetal hypoxemia develops acutely if abruption is severe, triggering compensatory responses (fetal tachycardia, redistribution of cardiac output to vital organs). Chronic partial abruption may present with signs of fetal growth restriction or oligohydramnios secondary to reduced placental perfusion.

• Coagulopathy—tissue factor activation and consumption coagulopathy: Disrupted placental tissue releases tissue factor (TF, also called Factor III) and placental thromboplastin into maternal circulation. This triggers the extrinsic coagulation cascade, leading to excessive thrombin generation and secondary fibrinolysis. The consuming coagulopathy results in depletion of fibrinogen (often dropping to critically low levels <100 mg/dL), platelets (consumptive thrombocytopenia), and factors V and VIII. Elevated D-dimer and fibrin degradation products (FDPs) reflect active fibrinolysis. This consumptive coagulopathy is the primary mechanism driving obstetric hemorrhage in severe abruption and distinguishes it from simple blood loss, making fresh frozen plasma and cryoprecipitate critical interventions.

• Uterine contractions and myometrial irritability: The decidual hemorrhage and disrupted placental interface trigger irritability of the myometrium, manifesting clinically as painful uterine contractions or "tetanic" uterine tone. This represents a local inflammatory response to tissue injury and may progress to frank labor.

Placenta Previa—Anatomic Obstruction Without Coagulopathy

• Low placental implantation site determination: The mechanisms governing trophoblastic implantation site selection are incompletely understood but involve altered endometrial receptivity. Defective decidualization, altered vascularization patterns, and abnormal uterine artery remodeling in the lower segment predispose to implantation in this location. The placenta, once implanted, does not migrate; rather, the lower uterine segment undergoes physiologic elongation and thinning during the second and third trimesters, which can shift a low-lying placenta away from the os (termed "placental migration").

• Mechanical obstruction of labor: When the placenta overlies the internal os, it physically blocks the fetal descent through the cervix during labor. Additionally, the lower uterine segment has reduced contractility compared with the fundus, further compromising the mechanical efficiency of labor. These mechanical factors necessitate cesarean delivery to prevent maternal hemorrhage and fetal compromise.

• Abnormal placentation physiology: Placenta previa is frequently associated with placenta accreta spectrum (abnormally invasive placenta), likely due to shared pathophysiology of altered decidualization and impaired trophoblastic invasion regulation. In severe forms (accreta, increta, or percreta), the chorionic villi invade deeply into or through the myometrium, preventing normal placental separation at delivery. This can lead to massive hemorrhage, hysterectomy, or maternal death.

• Absence of systemic coagulopathy: Unlike abruption, placenta previa does not trigger release of tissue factor or consumptive coagulopathy because the placenta remains attached to the decidua. Bleeding is primarily from the lower uterine segment vasculature exposed when the placenta separates from an abnormal implantation site. This distinction is critical: FFP and cryoprecipitate are not indicated for uncomplicated previa bleeding in the absence of coagulopathy.

PLACENTA PREVIA

• Maternal age ≥35 years: Advanced maternal age is one of the most consistent independent risk factors, with incidence increasing from approximately 0.3% in women <20 years to >1% in women >40 years. Proposed mechanisms include altered endometrial receptivity, reduced endometrial perfusion, and cumulative effects of prior instrumentation or inflammation.

• Prior cesarean delivery: Each prior cesarean section increases the risk substantially, with cumulative incidence reaching 4-5% after three prior cesareans. The mechanism involves disruption of the endometrial-myometrial interface and defective decidualization at the lower uterine segment. This risk is further amplified when prior cesarean delivery was for an anterior uterine indication (e.g., prior placenta previa or accreta).

• Multiparity and increased parity: Grand multiparity (≥5 prior deliveries) increases risk through mechanisms of endometrial atrophy and altered vascularization patterns. Paradoxically, some studies demonstrate lower risk in multiparous women without prior surgery, suggesting that parity alone may be protective.

• Placenta accreta spectrum (abnormally invasive placenta): Previa with prior cesarean section confers up to 50% risk of coexisting placenta accreta, and this risk increases exponentially with each additional prior cesarean (>50% after 3+ priors with previa). The shared pathophysiology of both conditions—defective decidualization and trophoblastic invasion dysregulation—explains this association.

• Intrauterine abnormalities: Uterine fibroids (especially submucous myomas), uterine anomalies (septate or bicornuate uterus), and previous uterine curettage for dilation and curettage (D&C) or miscarriage management impair endometrial receptivity and increase implantation in lower segments.

• In vitro fertilization (IVF) and assisted reproductive technology: IVF confers a 2-3 fold increased risk, independent of maternal age, likely related to altered endometrial receptivity from ovarian hyperstimulation or embryo transfer technique.

• Smoking: Active smoking increases risk via effects on uteroplacental blood flow and endometrial vascularization; the association is dose-dependent.

• Cocaine use: Associated with increased risk, likely through effects on vascular tone and placental development.

PLACENTAL ABRUPTION

• Hypertension and preeclampsia: Maternal hypertension (chronic or gestational) is the single most consistent risk factor for abruption, increasing risk 2-5 fold. Preeclampsia further elevates risk substantially. The mechanism involves endothelial dysfunction, increased vascular reactivity, and placental ischemia from inadequate trophoblastic invasion and spiral artery remodeling.

• Placental insufficiency conditions: Intrauterine growth restriction (IUGR), fetal hypoxemia, and oligohydramnios are associated with increased abruption risk, suggesting a shared pathophysiology of placental underperfusion.

• Maternal trauma: Motor vehicle collisions, intimate partner violence, or direct abdominal trauma can precipitate abruption acutely through direct disruption of the placental interface. The risk is particularly elevated in the third trimester when placental separation is mechanically more feasible.

• Cocaine and amphetamine use: These sympathomimetic agents cause acute hypertension, vasoconstriction, and placental hypoperfusion, substantially increasing abruption risk. Cocaine use is associated with abruption in approximately 4-8% of pregnancies, a rate 7-10 fold higher than in the general population.

• Cigarette smoking: Smoking increases risk by approximately 2-3 fold through mechanisms of reduced placental perfusion, impaired placentation, and increased placental oxidative stress.

• Thrombophilia: Both inherited thrombophilias (Factor V Leiden, prothrombin G20210A mutation, antithrombin or protein C/S deficiency) and acquired thrombophilias (antiphospholipid syndrome) increase abruption risk through mechanisms of placental microinfarction and vessel thrombosis.

• Previous abruption: Recurrence risk is approximately 10-25%, substantially higher than the baseline population risk. This elevated recurrence is not entirely explained by baseline risk factors, suggesting inherent uterine pathology or constitutional predisposition.

• Polyhydramnios: Excessive amniotic fluid is associated with increased abruption risk, possibly through increased uterine tension and placental stress.

• Multifetal pregnancy: Twin and higher-order multiple gestations carry increased abruption risk, attributed to increased intrauterine pressure and higher rates of hypertensive complications.

PLACENTA PREVIA

• Painless vaginal bleeding: The cardinal symptom is spontaneous vaginal hemorrhage, typically occurring in the late second or third trimester (peak presentation 28-34 weeks). The bleeding is characteristically painless and may range from spotting to massive hemorrhage. The absence of pain is a key clinical discriminator from abruption. Bleeding may be preceded by intercourse, pelvic examination, or cervical instrumentation, but often occurs without identified precipitant. The volume of bleeding does not correlate with severity of previa—even small-volume bleeds warrant investigation because they may herald a sentinel bleed before massive hemorrhage.

• First episode bleeding often minor: The initial presentation frequently involves modest bleeding that may resolve spontaneously, creating a false sense of security. However, recurrent episodes are common, and subsequent bleeds may be life-threatening. Approximately 50% of women with previa diagnosed on mid-trimester ultrasound will have at least one bleeding episode during pregnancy.

• Absence of uterine contractions or maternal symptoms: Unlike abruption, previa does not cause painful contractions, maternal shock (unless major hemorrhage has occurred), or signs of placental insufficiency in the acute setting. Maternal vital signs are typically normal unless significant blood loss has transpired. This clinical distinction is critical for diagnosis.

• Fetal heart rate abnormalities variable: Fetal tachycardia or other FHR abnormalities develop only if bleeding has been severe enough to compromise placental perfusion acutely. In most cases of previa with modest bleeding, fetal status is reassuring.

• Physical examination findings minimal: On examination, the patient typically appears well-appearing unless hemorrhaging acutely. Vital signs should be assessed (tachycardia, hypotension suggest significant blood loss). Importantly, digital cervical examination should be deferred in the setting of known or suspected previa, as cervical examination can precipitate massive bleeding by traumatizing exposed placental tissue.

• Diagnosis confirmed by ultrasound, not clinical exam: Clinical examination is diagnostically unhelpful and potentially harmful in previa; diagnosis rests entirely on ultrasound visualization.

PLACENTAL ABRUPTION

• Vaginal bleeding with acute-onset abdominal pain: The classic presentation is third trimester vaginal bleeding accompanied by severe, sharp abdominal/back pain. The pain is often described as constant and severe, reflecting the irritated myometrium and expanding retroplacental hematoma. Pain severity may exceed what one would anticipate from the volume of visible vaginal bleeding, a critical clinical clue to substantial concealed hemorrhage.

• Concealed versus revealed bleeding: In revealed abruption (approximately 75-80% of cases), vaginal bleeding is apparent. In concealed abruption (20-25%), the fetus or membranes block the cervical os, and blood is retained behind the placenta; the patient may present with minimal or absent vaginal bleeding despite massive ongoing hemorrhage. This can lead to rapid maternal decompensation without warning, as blood accumulates retroplacentally. Clinical suspicion must remain high when severe symptoms (pain, shock, fetal distress) are disproportionate to visible bleeding.

• Maternal hemorrhagic shock: Depending on severity of abruption and bleeding volume, patients may present with signs and symptoms of hypovolemic shock: tachycardia (>100), hypotension (<90 systolic), decreased urine output, altered mental status. These findings reflect both external hemorrhage and concealed bleeding. Maternal shock can develop suddenly and may precede obvious fetal distress, necessitating aggressive resuscitation.

• Uterine tenderness and tetanic contractions: On palpation, the uterus is typically tender, especially over the site of abruption. Uterine tone may be increased or "tetanic" (sustained contraction without relaxation), reflecting myometrial irritability from blood dissecting into the myometrium. Women may report frequent, painful contractions ("labor-like" pain).

• Acute fetal distress patterns: Fetal heart rate abnormalities develop acutely and may be severe, including late decelerations, persistent bradycardia, absent variability, or sinusoidal pattern. These abnormalities reflect acute hypoxemia from reduced placental perfusion and may progress rapidly to fetal death if intervention is delayed. The severity of FHR changes often correlates with the magnitude of placental separation.

• Signs of preeclampsia/hemolysis-elevated liver enzymes-low platelets (HELLP) syndrome: Approximately 5-10% of abruptions are complicated by coexisting preeclampsia or HELLP syndrome. Patients may present with hypertension, proteinuria, right upper quadrant pain, and laboratory evidence of hemolysis and thrombocytopenia. This overlap complicates the clinical picture and necessitates comprehensive laboratory evaluation.

• Absence of findings on vaginal exam: Digital cervical examination may be performed (unlike in previa) and typically reveals a closed or partially dilated cervix without specific findings.

CLINICAL VARIANTS AND SEVERITY SPECTRUM

• Mild abruption: Bleeding may be modest or entirely concealed; maternal vital signs stable; fetal status reassuring on monitoring. Diagnosis may be made incidentally on ultrasound or suspected when maternal symptoms and exam findings seem disproportionate to visible bleeding.

• Moderate abruption: Active vaginal bleeding with maternal tachycardia, tender uterus, and concerning fetal heart rate findings. Coagulopathy begins to develop; fibrinogen and platelets may be mildly reduced.

• Severe (massive) abruption: Hemorrhagic shock, severe abdominal pain, tetanic uterine contractions, fetal bradycardia or absent heart rate, evidence of consumptive coagulopathy (fibrinogen <100 mg/dL, severe thrombocytopenia, prolonged PT/PTT). This represents an obstetric emergency requiring immediate delivery and massive transfusion.

CLINICAL ASSESSMENT—HISTORY AND PRESENTATION

• Painless bleeding ≈ previa; painful bleeding ≈ abruption: This is the most useful clinical discriminator. Previa characteristically presents with bleeding without pain (unless labor is concurrently developing). Abruption classically presents with bleeding AND pain.

• Timing and gestational age: Previa typically presents in the late second or early third trimester (after 20 weeks); abruption can occur at any gestational age but is more common in the third trimester. Previa may be diagnosed incidentally on mid-trimester ultrasound; abruption typically presents symptomatically.

• Prior obstetric history: Prior cesarean delivery raises previa risk substantially

Immediate stabilization (both diagnoses)

• ABCs and volume resuscitation: two large-bore IVs, left lateral tilt to relieve aortocaval compression, crystalloid, and type-and-crossmatch. Send CBC, type and screen, PT/aPTT, and fibrinogen — in pregnancy fibrinogen is physiologically high, so a "normal" value is relatively low and a falling level is the earliest marker of abruption-related consumptive coagulopathy.
• Continuous electronic fetal monitoring and maternal telemetry: the fetal tracing is the most sensitive early indicator of ongoing placental separation.
• Blood products: ACOG's obstetric hemorrhage guidance supports activating a massive transfusion protocol with balanced PRBC:FFP:platelet ratios; give cryoprecipitate or fibrinogen concentrate for hypofibrinogenemia. An antifibrinolytic (tranexamic acid) is supported by ACOG as an adjunct in refractory postpartum hemorrhage.
• Rho(D) immune globulin in all Rh-negative women with antepartum bleeding (ACOG Practice Bulletin on prevention of Rh D alloimmunization), with Kleihauer–Betke or flow cytometry to size the fetomaternal hemorrhage and dose additional immune globulin.

Expectant management (stable mother, reassuring fetus, preterm)

• Antenatal corticosteroids: betamethasone 12 mg IM x2, 24 hours apart for anticipated delivery between 24 0/7 and 33 6/7 weeks (ACOG).
• Magnesium sulfate for fetal neuroprotection when delivery before 32 weeks is expected.
• Pelvic rest for previa: no intercourse, no digital cervical exam, no vaginal instrumentation.

Definitive management

• Placenta previa: cesarean delivery is mandatory. ACOG timing guidance for uncomplicated previa is scheduled delivery in the late preterm/early term window (about 36 0/7–37 6/7 weeks); suspected placenta accreta spectrum is delivered earlier (roughly 34 0/7–35 6/7 weeks) at a center with MFM, blood bank, and gynecologic oncology/urology, typically by planned cesarean hysterectomy with the placenta left in situ.
• Abruption: delivery is the only definitive therapy. Nonreassuring tracing, maternal instability, or DIC mandates emergent cesarean. With fetal demise and a stable mother, vaginal delivery is preferred.

Contraindicated

• Digital cervical examination before ultrasound excludes previa.
• Trial of labor/vaginal delivery with placenta overlying the os.
• Tocolysis with nonreassuring fetal status, hemodynamic instability, or severe abruption.
• Methylergonovine if hypertension/preeclampsia coexists; carboprost in asthma.

Maternal — emergencies

• Disseminated intravascular coagulation: decidual tissue factor entering the maternal circulation drives thrombin generation and consumption of fibrinogen, platelets, and factors V/VIII. Signaled by oozing from IV sites, falling fibrinogen, prolonged PT/aPTT, and rising D-dimer. Emergency — the most feared complication of abruption and essentially never seen in uncomplicated previa.
• Hypovolemic/hemorrhagic shock: concealed abruption bleeds retroplacentally, so tachycardia, narrow pulse pressure, oliguria, and altered mentation may precede any visible blood. Emergency.
• Couvelaire uterus (uteroplacental apoplexy): blood dissects between myometrial fibers, producing a boggy, bluish, poorly contractile uterus at cesarean and refractory atony with postpartum hemorrhage.
• Postpartum hemorrhage: after previa, the lower uterine segment contracts poorly and cannot compress the placental bed; after abruption, atony plus DIC compounds bleeding. Emergency.
• Placenta accreta spectrum with cesarean hysterectomy: previa over a prior hysterotomy scar prevents normal cleavage; heralded by failure of placental separation and torrential bleeding. Sequelae include bladder/ureteral injury and permanent sterility.
• Acute kidney injury: acute tubular necrosis from hypoperfusion, or bilateral renal cortical necrosis if DIC microthrombi occlude the cortex — signaled by anuria that fails to respond to volume.
• Sheehan syndrome: pituitary infarction from hypotension; presents postpartum with failure of lactation and amenorrhea.

Fetal/neonatal

• Stillbirth and hypoxic-ischemic injury: loss of exchange surface; late decelerations, bradycardia, or a sinusoidal pattern signal decompensation. Emergency.
• Iatrogenic prematurity: RDS, IVH, NEC follow the medically indicated preterm delivery both conditions require.
• Fetal growth restriction: chronic abruption with recurrent marginal bleeding.
• Fetomaternal hemorrhage with alloimmunization: fetal cells cross the disrupted interface; detected by Kleihauer–Betke.

Treatment-related

• Massive transfusion: dilutional coagulopathy, citrate-induced hypocalcemia, hyperkalemia, TACO/TRALI.
• Antenatal corticosteroids: transient maternal hyperglycemia and a rise in the leukocyte count that can mimic infection.

• The one-line discriminator: painless bright-red third-trimester bleeding with a soft, non-tender uterus = previa; painful bleeding with a tender, rigid, hypertonic uterus = abruption.
• Single best next step in any third-trimester bleed: ultrasound (transabdominal, then transvaginal if needed) before any digital cervical exam. Transvaginal ultrasound is safe in previa — the probe angle keeps it from entering the os — and is the distractor most often gotten wrong. Speculum exam is acceptable once previa is excluded.
• Abruption is a clinical diagnosis: ultrasound has poor sensitivity for retroplacental clot, so a normal ultrasound never excludes abruption. Do not choose "reassure and discharge" on a negative scan.
• The association examiners love: prior cesarean + current previa = placenta accreta spectrum, with risk climbing steeply with each additional cesarean. ACOG recommends planned delivery at a center capable of cesarean hysterectomy.
• Cocaine and hypertension/preeclampsia are the classic abruption stems; maternal trauma/MVC is the other. After trauma, extended continuous fetal monitoring is the answer, not immediate discharge.
• Couvelaire uterus and DIC with hypofibrinogenemia belong to abruption only. If a stem gives previa plus a low fibrinogen, reconsider the diagnosis.
• Give Rho(D) immune globulin to every Rh-negative woman with antepartum bleeding and check a Kleihauer–Betke to size the fetomaternal hemorrhage (ACOG).
• Common distractors: vasa previa — painless bleeding at spontaneous rupture of membranes with abrupt fetal bradycardia/sinusoidal tracing, fetal rather than maternal blood loss; uterine rupture — loss of station, palpable fetal parts, prior classical hysterotomy. Also remember a low-lying placenta seen at the anatomy scan often resolves with lower-segment elongation — repeat imaging in the early third trimester rather than committing to cesarean.